Unknown PHASE2 INTERVENTIONAL 2-arm NCT05092217

Tirelizumab Plus Surgery vs Surgery Alone for Recurrent Nasopharyngeal Carcinoma

Tirelizumab Plus Surgery vs Surgery Alone for Recurrent Nasopharyngeal Carcinoma：a Prospecitve, Parallel, Phase II, Randomized Clinical Trial

Sponsor: Eye & ENT Hospital of Fudan University

Conditions Nasopharyngeal Carcinoma

Interventions Tirelizumab salvage surgery

Updated 4 times since 2021 Last updated: Oct 22, 2021 Started: Oct 20, 2021 Primary completion: Oct 20, 2023 Completion: Oct 20, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05092217, this PHASE2 trial focuses on Nasopharyngeal Carcinoma and remains ongoing. Sponsored by Eye & ENT Hospital of Fudan University, it has been updated 4 times since 2021, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

4 versions recorded

Nov 2024 — Present [monthly]

Unknown PHASE2

Status: Not Yet Recruiting → Unknown
Sep 2024 — Nov 2024 [monthly]

Not Yet Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE2
Nov 2021 — Jul 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Oct 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eye & ENT Hospital of Fudan University

Data source: Eye & ENT Hospital of Fudan University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.